Quantcast

Neurological Wellness Center’s Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer’s, Stroke and Brain Injury is Now Being Taught in a Newly Released Video

December 20, 2012

The Perispinal Enbrel Injection Procedure that Dramatically Reverses the Cognitive Deficits and Physical Impairments Caused by Alzheimer´s Disease, Stroke and Traumatic Brain Injury is Now Available in a $49 On-Line Course Offered by http://www.neurological-recovery-guide.com

(PRWEB) December 19, 2012

Neurological Wellness Center began holding perispinal injection technique training courses in the spring of 2011. Since then physicians, nurses and lay caregivers have come from around the world to their Center in Managua, Nicaragua for individualized instructional courses teaching this procedure. Presently Neurological Wellness Center remains the only institution in the world teaching this perispinal Enbrel injection procedure. For more information about Neurological Wellness Center´s perispinal injection courses, visit: http://reversealzheimersnow.com.

For many, flying to Managua, Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez M.D., created the Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 25-page e-book are now available online at http://www.neurological-recovery-guide.com.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

Common to Alzheimer´s, stroke and traumatic brain injury is excess inflammation in the brain. It is this self-perpetuating inflammation cascade that contributes to many of the impairments people experience.

Enbrel is a powerful anti-inflammatory agent. This drug is a fusion of two proteins that occur naturally in the human body. Enbrel (etanercept) received FDA approval in 1998 as a treatment of rheumatoid arthritis. The broad therapeutic role of Enbrel is based on the fact that Tumor Necrosis Factor-alpha (TNF-alpha) is the master regulator of the inflammatory response in many organ systems throughout the body. Enbrel is a large protein molecule that binds to TNF-alpha effectively neutralizing and down regulating the body´s inflammatory response. The diverse conditions for which, perispinal Enbrel may effectively treat can be compared, as an illustration, to ibuprofen. Just as ibuprofen can alleviate the symptoms of sunburn, headache, a sprained ankle or back pain, so too perispinal Enbrel can induce the recovery of functions lost for a variety of reasons due to excess inflammation in the brain.

The perispinal injection itself, as we teach it is extremely safe. The injection is a simple subcutaneous injection performed with a fine gauge half-inch needle. This injection is a unique form of subcutaneous injection. The precise location of the injection site and the proper positioning of the person receiving the injection are critical for successful administration. This procedure is illustrated in step-by-step fashion in the 24-minute video and 25-page e-book.

Safety issues pertaining to the drug Enbrel are covered on the Enbrel.com website. Although Enbrel is a widely used drug with over 400,000 Americans self-injecting it weekly, it is not suitable for everyone. The Enbrel dosing schedule we counsel in our on-line course is generally quite low compared to the maximums recommended by Amgen/Pfizer for the treatment of rheumatoid plaque psoriasis.

The general counsel is to initiate perispinal Enbrel treatment as soon as possible after suffering a stroke or traumatic brain injury. Oral minocycline is generally prescribed as a concomitant therapy. Minocycline is an antibiotic with an excellent safety record and, like Enbrel it reduces the effects of excess TNF-alpha in the brain. Minocycline has the capacity to enhance the efficacy of perispinal Enbrel treatments. All treatment is initiated on a trial basis. There is a wide range of outcomes. Some clients have experienced dramatic life-changing recoveries even when treatment was begun years after the stroke or traumatic brain injury.

TNF-alpha is a cytokine produced by monocyte and macrophage white blood cells, which acts as the master regulator of the human inflammatory response. Excess TNF-alpha in the brain can disrupt synaptic communication. Excess TNF-alpha triggers a cycle whereby toxic amyloid-beta is produced. This results in greater levels of pro-inflammatory TNF-alpha. Enbrel was developed to treat various inflammatory diseases by binding to TNF-alpha, effectively neutralizing its ability to act on cell membranes. Perispinal Enbrel treatment has a rapid effect reversing cognitive impairment and validating the role excess TNF-alpha plays in the disease processes of Alzheimer´s, stroke and traumatic brain injury. Enbrel´s long half-life (70 to 132 hours) enables a series of treatments to produce sequential progressive improvements in cognitive function that can be maintained long term. The standard method for delivering CNS-active medication to the brain is via the blood. Enbrel, a large protein molecule, is unable to cross the blood-brain barrier. A subcutaneous perispinal injection to the fatty tissues at the back of the neck enables etanercept to enter the brain by lymph and venous drainage assisted by gravity.”

To learn more about perispinal Enbrel as a treatment for Alzheimer´s, stroke or traumatic brain injury and to purchase this $49 on-line course, please visit: http://www.neurological-recovery-guide.com.

ncbi.nlm.nih.gov/pubmed/20796174

Therapeutic evaluation of etanercept in a model of traumatic brain injury.

ncbi.nlm.nih.gov/pubmed/21254790

Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.

ncbi.nlm.nih.gov/pubmed/11428551

Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct.

ncbi.nlm.nih.gov/pubmed/19027875

Perispinal etanercept for neuroinflammatory disorders.

ncbi.nlm.nih.gov/pubmed/19075734

Inflammatory cytokines in acute ischemic stroke.

neurologyindia.com/article.asp?issn=00283886;year=2012;volume=60;issue=1;spage=23;epage=28;aulast=Padma

Efficacy of minocycline in acute ischemic stroke: A single-blinded, placebo-controlled trial.

medpagetoday.com/Neurology/Strokes/6835

Minocycline Reduces Stroke Damage in Late-Presenting Patients.

neurology.org/content/69/14/1404.abstract

Minocycline treatment in acute stroke.

ncbi.nlm.nih.gov/pubmed/19091170

Inflammatory markers and stroke.

tobinick.com/videos/cognitive-and-neurological-improvement-after-the-inrs-patented-etanercept-treatment-four-years-after-stroke/

Cognitive and neurological improvement after the INR´s patented etanercept treatment four years after stroke.

strokebreakthrough.com/videos/rapid-improvement-8-years-after-stroke-with-the-patented-inr-local-etanercept-treatment/

Rapid improvement 8 years after stroke with the patented INR treatment.

sciencedirect.com/science/article/pii/S1090380108001808

Effects of Etanercept and Minocycline in a rat model of spinal cord injury.

ncbi.nlm.nih.gov/pmc/articles/PMC1785182/

TNF-alpha modulation for treatment of Alzheimerʼs disease, 6-month pilot study. MedGenMed 2006, 8:25. PubMed Abstract, Demonstrates the efficacy of perispinal Enbrel as a treatment for Alzheimerʼs disease.

lef.org/magazine/mag2008/aug2008_Novel-Drug-Therapy-Immediately-Reverses-Alzheimers-Cognitive-Deficits_01.htm

Novel drug therapy immediately reverses Alzheimerʼs cognitive deficits.

sciencedaily.com/releases/2008/01/080109091102.htm

Reversal of Alzheimerʼs symptoms within minutes in human study.

ncbi.nlm.nih.gov/pubmed/20518613

Perispinal etanercept: a new therapeutic paradigm in neurology.

stevensponauglewordpress.com, Enbrel injections reverse some Alzheimer´s disease symptoms.

Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer´s disease. BMC Neurol, 2008. 8: p.27.

Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer´s disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5: p.2.

Griffin, W.S., Perispinal etanercept: potential as an Alzheimer´s therapeutic. J Neuroinflammation, 2008. 5: p.3.

Tobinick, E., Perispinal etanercept for treatment of Alzheimer´s disease. Curr Alzheimer Res, 2007. 4(5): p.550-2.

McAlpine, F.E. and M.G. Tansey, Neuro-inflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer´s. J Inflammation Research, 2008. 1: p.29 39.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10188428.htm


Source: prweb



comments powered by Disqus